Notice of Proposed Sale · 144
Maze Therapeutics, Inc.
MAZENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Maze Therapeutics, Inc.
- Issuer CIK
- 0001842295
- SEC file number
- 001-42490
- Phone
- 6508505070
- Person for whose account securities are to be sold
- Coloma Jason V
- Relationships to issuer
- Officer
- Street
- 171 OYSTER POINT BOULEVARD, SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 34,501 | 933,252.05 | 55,549,168 | 10/01/2026 | Nasdaq | UBS Financial Services Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services Inc.
- Street
- Eleven Madison Avenue
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Donor acquired | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|---|
| Common | 09/22/2021 | Gift | Jason Coloma | 2,593 | Y | 11/01/2018 | 09/22/2021 | NA |
| Common | 09/22/2021 | Gift | Jason Coloma | 31,908 | Y | 06/24/2019 | 09/22/2021 | NA |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| The Coloma 2021 Irrevocable Trust DTD 09/20/2021 | Common | 08/03/2026 | 2,593 | 69,329.00 |
| The Coloma 2021 Irrevocable Trust DTD 09/20/2021 | Common | 07/01/2026 | 2,593 | 77,726.21 |
| Coloma Family Trust DTD 06/27/2016 | Common | 08/03/2026 | 31,908 | 852,983.80 |
| Coloma Family Trust DTD 06/27/2016 | Common | 07/01/2026 | 31,908 | 956,528.45 |
| The Coloma 2021 Irrevocable Trust DTD 09/20/2021 | Common | 09/01/2026 | 2,593 | 68,214.05 |
| Coloma Family Trust DTD 06/27/2016 | Common | 09/01/2026 | 31,908 | 838,784.74 |
Seller — prior-sale row 1, entry 1
- Name
- The Coloma 2021 Irrevocable Trust DTD 09/20/2021
- Street
- 171 OYSTER POINT BOULEVARD, SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 2, entry 1
- Name
- The Coloma 2021 Irrevocable Trust DTD 09/20/2021
- Street
- 171 OYSTER POINT BOULEVARD, SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 3, entry 1
- Name
- Coloma Family Trust DTD 06/27/2016
- Street
- 171 OYSTER POINT BOULEVARD, SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 4, entry 1
- Name
- Coloma Family Trust DTD 06/27/2016
- Street
- 171 OYSTER POINT BOULEVARD, SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 5, entry 1
- Name
- The Coloma 2021 Irrevocable Trust DTD 09/20/2021
- Street
- 171 OYSTER POINT BOULEVARD
- Street (continued)
- Suite 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 6, entry 1
- Name
- Coloma Family Trust DTD 06/27/2016
- Street
- 171 OYSTER POINT BOULEVARD
- Street (continued)
- SUITE 300
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
2,593 shares for this filing were sold under The Coloma 2021 Irrevocable Trust DTD 09/20/2021 and 31,908 shares were sold under Coloma Family Trust DTD 06/27/2016
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ UBS Financial Services Inc., as attorney-in-fact for Jason Coloma as trustee
- Plan adoption dates
- 02/06/2026
Company context
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.